Concepts (286)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Medication Adherence | 25 | 2025 | 326 | 7.240 |
Why?
|
| Medicare Part C | 12 | 2025 | 34 | 5.530 |
Why?
|
| Motivational Interviewing | 7 | 2023 | 48 | 4.550 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 11 | 2025 | 742 | 4.230 |
Why?
|
| Hypertension | 13 | 2025 | 1397 | 3.660 |
Why?
|
| Hyperlipidemias | 5 | 2022 | 188 | 3.180 |
Why?
|
| Diabetes Mellitus | 10 | 2025 | 923 | 2.600 |
Why?
|
| Atrial Fibrillation | 6 | 2025 | 737 | 2.590 |
Why?
|
| Smoking Cessation | 7 | 2016 | 191 | 2.590 |
Why?
|
| Antihypertensive Agents | 6 | 2025 | 429 | 2.520 |
Why?
|
| Anticoagulants | 5 | 2025 | 607 | 2.380 |
Why?
|
| Hypoglycemic Agents | 5 | 2025 | 482 | 2.330 |
Why?
|
| Smoking | 8 | 2016 | 941 | 1.820 |
Why?
|
| Angiotensin Receptor Antagonists | 7 | 2025 | 137 | 1.770 |
Why?
|
| United States | 42 | 2025 | 11660 | 1.740 |
Why?
|
| Aged | 48 | 2025 | 21426 | 1.700 |
Why?
|
| Medicare | 15 | 2025 | 447 | 1.680 |
Why?
|
| Retrospective Studies | 49 | 2025 | 17389 | 1.580 |
Why?
|
| Medicare Part D | 2 | 2021 | 13 | 1.360 |
Why?
|
| Cardiovascular Diseases | 8 | 2025 | 2089 | 1.290 |
Why?
|
| Diabetes Mellitus, Type 2 | 5 | 2025 | 1411 | 1.280 |
Why?
|
| Pharmaceutical Services | 3 | 2021 | 36 | 1.180 |
Why?
|
| Antipsychotic Agents | 7 | 2025 | 381 | 1.150 |
Why?
|
| Administration, Oral | 7 | 2025 | 696 | 1.090 |
Why?
|
| Drug Therapy, Combination | 8 | 2025 | 1177 | 1.080 |
Why?
|
| Rivaroxaban | 2 | 2024 | 57 | 1.060 |
Why?
|
| Factor Xa Inhibitors | 2 | 2024 | 66 | 1.040 |
Why?
|
| Stroke | 3 | 2025 | 1081 | 1.040 |
Why?
|
| Pyridones | 2 | 2024 | 131 | 1.020 |
Why?
|
| Markov Chains | 2 | 2024 | 101 | 1.020 |
Why?
|
| Aged, 80 and over | 17 | 2025 | 7107 | 1.000 |
Why?
|
| Quality-Adjusted Life Years | 2 | 2024 | 141 | 1.000 |
Why?
|
| Varenicline | 2 | 2016 | 12 | 0.980 |
Why?
|
| Bupropion | 2 | 2016 | 29 | 0.970 |
Why?
|
| Humans | 85 | 2025 | 132064 | 0.950 |
Why?
|
| Breast Neoplasms | 11 | 2025 | 2647 | 0.950 |
Why?
|
| Multiple Myeloma | 2 | 2025 | 202 | 0.940 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 6 | 2023 | 222 | 0.910 |
Why?
|
| Pyrazoles | 2 | 2024 | 332 | 0.900 |
Why?
|
| Female | 61 | 2025 | 70664 | 0.890 |
Why?
|
| Monte Carlo Method | 1 | 2024 | 102 | 0.860 |
Why?
|
| Administrative Claims, Healthcare | 2 | 2021 | 16 | 0.860 |
Why?
|
| Cost-Benefit Analysis | 2 | 2024 | 576 | 0.850 |
Why?
|
| Male | 51 | 2025 | 64938 | 0.840 |
Why?
|
| Hemorrhage | 2 | 2025 | 519 | 0.830 |
Why?
|
| Weight Gain | 4 | 2025 | 381 | 0.820 |
Why?
|
| Practice Patterns, Physicians' | 6 | 2019 | 767 | 0.800 |
Why?
|
| Obesity | 6 | 2023 | 2398 | 0.790 |
Why?
|
| Middle Aged | 32 | 2025 | 28993 | 0.780 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2025 | 1305 | 0.760 |
Why?
|
| Texas | 14 | 2024 | 3627 | 0.730 |
Why?
|
| Warfarin | 2 | 2022 | 127 | 0.730 |
Why?
|
| Students | 3 | 2013 | 263 | 0.720 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2025 | 1340 | 0.710 |
Why?
|
| Logistic Models | 11 | 2021 | 1839 | 0.700 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2025 | 807 | 0.650 |
Why?
|
| Students, Pharmacy | 2 | 2019 | 69 | 0.630 |
Why?
|
| Cholinesterase Inhibitors | 3 | 2024 | 98 | 0.630 |
Why?
|
| Hepatic Encephalopathy | 1 | 2020 | 84 | 0.610 |
Why?
|
| Benchmarking | 1 | 2020 | 138 | 0.610 |
Why?
|
| Social Determinants of Health | 1 | 2021 | 155 | 0.600 |
Why?
|
| Estrogen Antagonists | 1 | 2018 | 97 | 0.570 |
Why?
|
| Cancer Survivors | 2 | 2018 | 247 | 0.570 |
Why?
|
| Medicaid | 4 | 2025 | 251 | 0.570 |
Why?
|
| Drug Prescriptions | 1 | 2020 | 238 | 0.570 |
Why?
|
| Buprenorphine | 3 | 2025 | 101 | 0.550 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2021 | 326 | 0.530 |
Why?
|
| Hospitalization | 3 | 2020 | 1900 | 0.530 |
Why?
|
| Health Care Costs | 1 | 2020 | 415 | 0.520 |
Why?
|
| Adult | 31 | 2025 | 31571 | 0.510 |
Why?
|
| Cross-Sectional Studies | 15 | 2025 | 3760 | 0.500 |
Why?
|
| Patient Readmission | 1 | 2020 | 425 | 0.500 |
Why?
|
| Drug Combinations | 4 | 2020 | 280 | 0.490 |
Why?
|
| Arabs | 1 | 2015 | 30 | 0.490 |
Why?
|
| Schizophrenic Psychology | 1 | 2016 | 85 | 0.490 |
Why?
|
| Dopamine Uptake Inhibitors | 1 | 2015 | 35 | 0.480 |
Why?
|
| Nicotinic Agonists | 1 | 2015 | 38 | 0.480 |
Why?
|
| Opioid-Related Disorders | 3 | 2025 | 285 | 0.470 |
Why?
|
| Tobacco Use Disorder | 1 | 2016 | 87 | 0.460 |
Why?
|
| Universities | 3 | 2013 | 129 | 0.460 |
Why?
|
| Tobacco Products | 1 | 2015 | 72 | 0.460 |
Why?
|
| Blood Glucose | 5 | 2025 | 1121 | 0.440 |
Why?
|
| Suicide, Attempted | 1 | 2016 | 154 | 0.440 |
Why?
|
| Primary Health Care | 1 | 2021 | 793 | 0.440 |
Why?
|
| Young Adult | 14 | 2025 | 9952 | 0.430 |
Why?
|
| Schizophrenia | 1 | 2016 | 332 | 0.400 |
Why?
|
| Telephone | 3 | 2019 | 123 | 0.390 |
Why?
|
| Health Behavior | 1 | 2015 | 399 | 0.390 |
Why?
|
| Pharmacists | 3 | 2020 | 102 | 0.380 |
Why?
|
| Social Perception | 1 | 2013 | 56 | 0.380 |
Why?
|
| Risk-Taking | 2 | 2012 | 101 | 0.370 |
Why?
|
| Nicotine | 1 | 2013 | 118 | 0.370 |
Why?
|
| Insurance, Pharmaceutical Services | 2 | 2016 | 9 | 0.350 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2025 | 605 | 0.340 |
Why?
|
| Healthcare Disparities | 3 | 2025 | 485 | 0.330 |
Why?
|
| Cyclin-Dependent Kinase 4 | 3 | 2025 | 64 | 0.320 |
Why?
|
| Opiate Substitution Treatment | 3 | 2025 | 32 | 0.310 |
Why?
|
| Social Class | 2 | 2024 | 206 | 0.300 |
Why?
|
| Physicians | 4 | 2019 | 640 | 0.300 |
Why?
|
| Body Mass Index | 7 | 2025 | 1698 | 0.290 |
Why?
|
| Patient Acceptance of Health Care | 3 | 2024 | 482 | 0.290 |
Why?
|
| Adolescent | 16 | 2025 | 20542 | 0.290 |
Why?
|
| Disease Management | 1 | 2012 | 563 | 0.290 |
Why?
|
| Patient Compliance | 2 | 2015 | 473 | 0.280 |
Why?
|
| Hydrocodone | 2 | 2019 | 37 | 0.280 |
Why?
|
| Cyclin-Dependent Kinase 6 | 2 | 2025 | 49 | 0.270 |
Why?
|
| Interrupted Time Series Analysis | 2 | 2024 | 28 | 0.270 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2020 | 259 | 0.270 |
Why?
|
| Alzheimer Disease | 2 | 2024 | 857 | 0.250 |
Why?
|
| Proportional Hazards Models | 3 | 2020 | 1457 | 0.250 |
Why?
|
| Analgesics, Opioid | 3 | 2024 | 471 | 0.240 |
Why?
|
| Polypharmacy | 1 | 2005 | 36 | 0.240 |
Why?
|
| Health Expenditures | 2 | 2024 | 133 | 0.240 |
Why?
|
| Follow-Up Studies | 3 | 2020 | 5412 | 0.230 |
Why?
|
| Proteasome Inhibitors | 1 | 2025 | 61 | 0.230 |
Why?
|
| Health Services Accessibility | 2 | 2025 | 669 | 0.230 |
Why?
|
| Health Maintenance Organizations | 1 | 2004 | 20 | 0.220 |
Why?
|
| Risk Factors | 8 | 2024 | 10938 | 0.220 |
Why?
|
| Aromatase Inhibitors | 3 | 2020 | 78 | 0.220 |
Why?
|
| Central Nervous System Stimulants | 1 | 2025 | 128 | 0.220 |
Why?
|
| Dabigatran | 1 | 2024 | 29 | 0.220 |
Why?
|
| Narcotic Antagonists | 1 | 2025 | 110 | 0.220 |
Why?
|
| Thalidomide | 1 | 2024 | 40 | 0.210 |
Why?
|
| Delirium | 1 | 2024 | 61 | 0.210 |
Why?
|
| Longitudinal Studies | 2 | 2025 | 1500 | 0.210 |
Why?
|
| Confidence Intervals | 3 | 2013 | 277 | 0.200 |
Why?
|
| Ambulatory Care | 2 | 2020 | 410 | 0.200 |
Why?
|
| Hypnotics and Sedatives | 1 | 2024 | 136 | 0.200 |
Why?
|
| Hypolipidemic Agents | 1 | 2004 | 189 | 0.190 |
Why?
|
| Cytochrome P-450 CYP3A Inhibitors | 1 | 2022 | 11 | 0.190 |
Why?
|
| Databases, Factual | 2 | 2024 | 1230 | 0.190 |
Why?
|
| Antidepressive Agents | 1 | 2025 | 327 | 0.190 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2022 | 50 | 0.190 |
Why?
|
| Health Status Disparities | 1 | 2024 | 253 | 0.180 |
Why?
|
| Cognition Disorders | 1 | 2005 | 569 | 0.180 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2023 | 1127 | 0.180 |
Why?
|
| Pharmacies | 1 | 2021 | 15 | 0.170 |
Why?
|
| Hypertriglyceridemia | 1 | 2022 | 114 | 0.170 |
Why?
|
| Pharmacy | 1 | 2021 | 19 | 0.170 |
Why?
|
| Health Surveys | 2 | 2012 | 259 | 0.170 |
Why?
|
| Surveys and Questionnaires | 6 | 2023 | 3993 | 0.170 |
Why?
|
| Tamoxifen | 2 | 2020 | 349 | 0.170 |
Why?
|
| Qualitative Research | 1 | 2024 | 664 | 0.170 |
Why?
|
| Odds Ratio | 3 | 2013 | 1255 | 0.170 |
Why?
|
| Comorbidity | 2 | 2016 | 1606 | 0.170 |
Why?
|
| Diabetes Complications | 1 | 2022 | 208 | 0.170 |
Why?
|
| Breast Neoplasms, Male | 1 | 2020 | 16 | 0.170 |
Why?
|
| Controlled Substances | 2 | 2019 | 11 | 0.170 |
Why?
|
| Metformin | 1 | 2022 | 166 | 0.170 |
Why?
|
| HIV Infections | 3 | 2023 | 2047 | 0.160 |
Why?
|
| Neomycin | 1 | 2020 | 36 | 0.160 |
Why?
|
| Lactulose | 1 | 2020 | 29 | 0.160 |
Why?
|
| Sex Factors | 2 | 2019 | 1351 | 0.160 |
Why?
|
| Receptor, ErbB-2 | 4 | 2025 | 518 | 0.160 |
Why?
|
| Sexual Behavior | 2 | 2013 | 250 | 0.160 |
Why?
|
| Gastrointestinal Agents | 1 | 2020 | 64 | 0.160 |
Why?
|
| Health Knowledge, Attitudes, Practice | 4 | 2022 | 899 | 0.160 |
Why?
|
| Acute Pain | 1 | 2019 | 17 | 0.150 |
Why?
|
| Military Personnel | 2 | 2013 | 203 | 0.150 |
Why?
|
| Forecasting | 1 | 2021 | 372 | 0.150 |
Why?
|
| Psychological Theory | 2 | 2016 | 37 | 0.150 |
Why?
|
| Treatment Outcome | 3 | 2025 | 13000 | 0.150 |
Why?
|
| Substance-Related Disorders | 1 | 2023 | 491 | 0.150 |
Why?
|
| Metabolic Syndrome | 1 | 2022 | 365 | 0.150 |
Why?
|
| Cholesterol, LDL | 1 | 2022 | 606 | 0.150 |
Why?
|
| Intention | 2 | 2016 | 101 | 0.140 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2020 | 213 | 0.140 |
Why?
|
| Health Services | 1 | 2018 | 70 | 0.140 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2021 | 236 | 0.140 |
Why?
|
| Standard of Care | 1 | 2018 | 134 | 0.140 |
Why?
|
| Multivariate Analysis | 3 | 2012 | 1439 | 0.140 |
Why?
|
| Quinolines | 1 | 2019 | 120 | 0.140 |
Why?
|
| Health Care Surveys | 2 | 2019 | 294 | 0.140 |
Why?
|
| Program Evaluation | 1 | 2019 | 453 | 0.140 |
Why?
|
| Prospective Studies | 2 | 2019 | 6570 | 0.130 |
Why?
|
| Venous Thrombosis | 1 | 2019 | 171 | 0.130 |
Why?
|
| Age Factors | 2 | 2019 | 2911 | 0.130 |
Why?
|
| Chronic Pain | 1 | 2019 | 149 | 0.130 |
Why?
|
| Decision Support Techniques | 1 | 2020 | 310 | 0.130 |
Why?
|
| Chronic Disease | 1 | 2021 | 1234 | 0.130 |
Why?
|
| Insulin Resistance | 1 | 2022 | 698 | 0.130 |
Why?
|
| Perception | 2 | 2022 | 237 | 0.130 |
Why?
|
| Middle East | 2 | 2016 | 34 | 0.130 |
Why?
|
| Pulmonary Embolism | 1 | 2019 | 189 | 0.130 |
Why?
|
| Smoking Prevention | 1 | 2016 | 33 | 0.120 |
Why?
|
| Recurrence | 1 | 2020 | 1454 | 0.120 |
Why?
|
| Depression | 1 | 2025 | 1339 | 0.120 |
Why?
|
| Health Planning Guidelines | 1 | 2016 | 34 | 0.120 |
Why?
|
| Medication Therapy Management | 1 | 2016 | 23 | 0.120 |
Why?
|
| Mental Disorders | 1 | 2023 | 888 | 0.120 |
Why?
|
| Self-Injurious Behavior | 1 | 2016 | 66 | 0.120 |
Why?
|
| Pilot Projects | 1 | 2020 | 1442 | 0.120 |
Why?
|
| Linear Models | 1 | 2017 | 713 | 0.110 |
Why?
|
| Physician-Patient Relations | 1 | 2018 | 448 | 0.110 |
Why?
|
| Child | 9 | 2025 | 25763 | 0.110 |
Why?
|
| Cohort Studies | 3 | 2018 | 5168 | 0.110 |
Why?
|
| Cholinergic Antagonists | 2 | 2024 | 46 | 0.110 |
Why?
|
| Socioeconomic Factors | 3 | 2025 | 902 | 0.100 |
Why?
|
| Risk | 1 | 2015 | 761 | 0.100 |
Why?
|
| Blood Pressure | 1 | 2019 | 1400 | 0.100 |
Why?
|
| Propylene Glycol | 1 | 2013 | 9 | 0.100 |
Why?
|
| Social Values | 1 | 2013 | 48 | 0.100 |
Why?
|
| Nebulizers and Vaporizers | 1 | 2013 | 59 | 0.100 |
Why?
|
| Pakistan | 1 | 2012 | 94 | 0.100 |
Why?
|
| Jordan | 1 | 2012 | 9 | 0.090 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2013 | 95 | 0.090 |
Why?
|
| India | 1 | 2012 | 238 | 0.090 |
Why?
|
| Focus Groups | 1 | 2013 | 224 | 0.090 |
Why?
|
| Sunlight | 1 | 2011 | 26 | 0.090 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2018 | 626 | 0.090 |
Why?
|
| Early Detection of Cancer | 1 | 2015 | 414 | 0.090 |
Why?
|
| Overweight | 1 | 2014 | 383 | 0.090 |
Why?
|
| Data Collection | 1 | 2013 | 391 | 0.090 |
Why?
|
| Health Personnel | 1 | 2016 | 543 | 0.080 |
Why?
|
| Self Report | 1 | 2014 | 549 | 0.080 |
Why?
|
| Vitamin D Deficiency | 1 | 2011 | 74 | 0.080 |
Why?
|
| HIV Seropositivity | 1 | 2011 | 128 | 0.080 |
Why?
|
| Cholesterol | 2 | 2023 | 558 | 0.080 |
Why?
|
| Vitamin D | 1 | 2011 | 183 | 0.080 |
Why?
|
| Public Health | 1 | 2012 | 281 | 0.080 |
Why?
|
| Receptors, Estrogen | 2 | 2025 | 730 | 0.080 |
Why?
|
| Receptors, Progesterone | 2 | 2025 | 679 | 0.080 |
Why?
|
| Drug and Narcotic Control | 2 | 2019 | 16 | 0.070 |
Why?
|
| Anti-Bacterial Agents | 1 | 2020 | 2554 | 0.070 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2020 | 393 | 0.070 |
Why?
|
| Incidence | 1 | 2015 | 3375 | 0.070 |
Why?
|
| Case-Control Studies | 2 | 2023 | 3412 | 0.060 |
Why?
|
| Electronic Health Records | 2 | 2025 | 801 | 0.060 |
Why?
|
| Purines | 1 | 2025 | 113 | 0.060 |
Why?
|
| New England | 1 | 2004 | 12 | 0.060 |
Why?
|
| Aminopyridines | 1 | 2025 | 55 | 0.060 |
Why?
|
| Child Psychiatry | 1 | 2024 | 16 | 0.060 |
Why?
|
| Drug Utilization | 1 | 2005 | 166 | 0.060 |
Why?
|
| Benzimidazoles | 1 | 2025 | 132 | 0.050 |
Why?
|
| Aripiprazole | 1 | 2024 | 22 | 0.050 |
Why?
|
| Drug Administration Schedule | 1 | 2005 | 748 | 0.050 |
Why?
|
| Treatment Refusal | 1 | 2004 | 80 | 0.050 |
Why?
|
| Regression Analysis | 1 | 2005 | 795 | 0.050 |
Why?
|
| Pyridines | 1 | 2025 | 249 | 0.050 |
Why?
|
| Patient Acuity | 1 | 2023 | 67 | 0.050 |
Why?
|
| Residence Characteristics | 1 | 2005 | 286 | 0.050 |
Why?
|
| Piperazines | 1 | 2025 | 255 | 0.050 |
Why?
|
| Drug Monitoring | 1 | 2024 | 175 | 0.050 |
Why?
|
| Immunologic Factors | 1 | 2024 | 184 | 0.050 |
Why?
|
| Mortality | 1 | 2004 | 263 | 0.050 |
Why?
|
| Interviews as Topic | 1 | 2024 | 426 | 0.050 |
Why?
|
| Managed Care Programs | 1 | 2022 | 56 | 0.050 |
Why?
|
| Health Status | 1 | 2024 | 407 | 0.050 |
Why?
|
| Obesity, Abdominal | 1 | 2022 | 41 | 0.050 |
Why?
|
| Nigeria | 2 | 2013 | 70 | 0.050 |
Why?
|
| Mexico | 1 | 2022 | 187 | 0.050 |
Why?
|
| Lipoproteins, HDL | 1 | 2022 | 117 | 0.050 |
Why?
|
| Postmenopause | 1 | 2022 | 153 | 0.050 |
Why?
|
| Sexual Partners | 2 | 2013 | 85 | 0.040 |
Why?
|
| Minority Groups | 1 | 2023 | 249 | 0.040 |
Why?
|
| Research | 1 | 2023 | 265 | 0.040 |
Why?
|
| Neoplasms | 1 | 2016 | 2952 | 0.040 |
Why?
|
| Coronary Disease | 1 | 2004 | 685 | 0.040 |
Why?
|
| Attitude of Health Personnel | 2 | 2016 | 726 | 0.040 |
Why?
|
| Mastectomy | 1 | 2020 | 75 | 0.040 |
Why?
|
| Aftercare | 1 | 2021 | 155 | 0.040 |
Why?
|
| Lipids | 1 | 2022 | 561 | 0.040 |
Why?
|
| Breast | 1 | 2020 | 215 | 0.040 |
Why?
|
| Analgesics | 1 | 2019 | 127 | 0.040 |
Why?
|
| Cognition | 1 | 2023 | 810 | 0.040 |
Why?
|
| Survival Rate | 1 | 2023 | 2193 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2020 | 820 | 0.030 |
Why?
|
| United States Government Agencies | 1 | 2016 | 5 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2020 | 1360 | 0.030 |
Why?
|
| Models, Psychological | 1 | 2016 | 143 | 0.030 |
Why?
|
| Pandemics | 1 | 2023 | 1185 | 0.030 |
Why?
|
| Reimbursement, Incentive | 1 | 2016 | 49 | 0.030 |
Why?
|
| Fluorouracil | 1 | 2015 | 138 | 0.030 |
Why?
|
| Mammography | 1 | 2015 | 132 | 0.030 |
Why?
|
| SEER Program | 1 | 2015 | 220 | 0.030 |
Why?
|
| Saudi Arabia | 1 | 2013 | 41 | 0.030 |
Why?
|
| Cisplatin | 1 | 2015 | 280 | 0.030 |
Why?
|
| Methotrexate | 1 | 2015 | 350 | 0.020 |
Why?
|
| Communication | 1 | 2016 | 542 | 0.020 |
Why?
|
| Protease Inhibitors | 1 | 2011 | 97 | 0.020 |
Why?
|
| Registries | 1 | 2018 | 1596 | 0.020 |
Why?
|
| Condoms | 1 | 2010 | 51 | 0.020 |
Why?
|
| Self Efficacy | 1 | 2010 | 207 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2024 | 14734 | 0.020 |
Why?
|
| Prevalence | 1 | 2011 | 2657 | 0.010 |
Why?
|
| Heart Failure | 1 | 2016 | 2401 | 0.010 |
Why?
|